Nevro Corp (NYSE:NVRO) VP Michael Enxing sold 1,500 shares of the business’s stock in a transaction on Tuesday, April 4th. The shares were sold at an average price of $93.53, for a total transaction of $140,295.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Michael Enxing also recently made the following trade(s):
- On Monday, March 6th, Michael Enxing sold 38,500 shares of Nevro Corp stock. The shares were sold at an average price of $91.01, for a total transaction of $3,503,885.00.
Shares of Nevro Corp (NYSE:NVRO) traded down 3.01% during midday trading on Friday, reaching $85.06. 294,942 shares of the company’s stock traded hands. The firm’s market capitalization is $2.48 billion. Nevro Corp has a 52-week low of $61.52 and a 52-week high of $106.93. The stock’s 50 day moving average price is $91.81 and its 200 day moving average price is $88.25.
Nevro Corp (NYSE:NVRO) last released its quarterly earnings results on Thursday, February 23rd. The medical equipment provider reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.14. The business had revenue of $70.50 million for the quarter, compared to analyst estimates of $66.41 million. Nevro Corp had a negative return on equity of 14.57% and a negative net margin of 18.91%. The company’s revenue for the quarter was up 113.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) EPS. On average, equities research analysts anticipate that Nevro Corp will post ($0.54) EPS for the current fiscal year.
Several brokerages have recently issued reports on NVRO. B. Riley reissued a “buy” rating and set a $108.00 price target on shares of Nevro Corp in a report on Friday, February 24th. Zacks Investment Research raised shares of Nevro Corp from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Wednesday, December 28th. Northland Securities reaffirmed a “positive” rating and issued a $110.00 price objective on shares of Nevro Corp in a report on Thursday, February 2nd. Leerink Swann upped their price objective on shares of Nevro Corp from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Friday, February 24th. Finally, Canaccord Genuity started coverage on shares of Nevro Corp in a report on Thursday, March 23rd. They issued a “buy” rating and a $120.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Nevro Corp currently has an average rating of “Buy” and a consensus target price of $103.18.
Several large investors have recently added to or reduced their stakes in NVRO. SG Americas Securities LLC acquired a new stake in Nevro Corp during the third quarter worth approximately $239,000. Aperio Group LLC acquired a new stake in Nevro Corp during the third quarter worth approximately $246,000. Massmutual Trust Co. FSB ADV acquired a new stake in Nevro Corp during the fourth quarter worth approximately $177,000. Creative Planning raised its stake in Nevro Corp by 1,179.5% in the third quarter. Creative Planning now owns 2,495 shares of the medical equipment provider’s stock worth $260,000 after buying an additional 2,300 shares in the last quarter. Finally, TD Asset Management Inc. acquired a new stake in Nevro Corp during the third quarter worth approximately $281,000.
Nevro Corp Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.